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Abstract
Breast cancer is a complex disease, and it is the most common cause of morbidity and mortality among women worldwide. In
Sub-Saharan Africa, the clinical characteristics and tumor profiles of breast cancer are still unknown. In the present study we
aimed to determine breast tumor profiles of the Rwandan patients in relation to age and tumor stages. We compare our findings to
related results from other sub-Saharan Africa studies. Data on age at diagnosis, tumor stage, and hormonal profiles of 138 patients
diagnosed between January 2015 and December 2018 were retrospectively retrieved from electronic medical records at three
referral hospitals in Rwanda. We compared our results to related findings reported in other Sub-Saharan African countries. All
statistical analyses were done using SPSS Inc., Chicago, IL, USA, version 20 and R software languages. The mean age at
diagnosis was 49.7 years (SD = 13) and ranged from 17 to 86 years. The majority of patients (57.2%) were diagnosed before
50 years of age comparedwith 42.8% aged > 50 years. Tumor stage III was the commonest accounting for 62% followed by stage
II with 24.8%. The distribution of breast tumor subtypes was ER−, PR−, HER2−: 37.7%; ER+, PR+, HER2−: 31.2%; ER−, PR−,
HER2+: 14.5%; ER+, PR+, HER2+: 5.1%; and other subtypes represented 11.6%. There was no statistically significant differ-
ence in age and tumor stages between the molecular subtypes. Our findings revealed the predominance of hormonal negative
tumors among Rwandan patients with breast cancer. Triple negative was found to be the most common breast tumor subtype
regardless of age and tumor stage. Larger prospective studies could examine genetics and environmental factors that may play a
role in the differences of tumor characteristics in Sub-Saharan populations.
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Background
Breast cancer (BC) is the most commonly diagnosed and
deadly malignancy in women in both developed and develop-
ing countries with about 2.1 million cases and 627,000 deaths
registered in 2018 [1]. It causes 25.1% of all cancer deaths
each year in developed countries and is the leading cause of
mortality among women in developing countries with 14.3%
of all deaths annually. The GLOBOCAN estimates that the
BC incidence will double by the year 2050 [2].
In Sub-Saharan Africa (SSA), BC is becoming a serious
public health issue with a significant increase in its incidence,
and a high mortality rate as compared with developed parts of
the world [3, 4]. In Rwanda, a small country of 26,338 km2
and more than 12million inhabitants, BC is currently the most
commonly diagnosed cancer in women and the second cause
of mortality after cervical cancer [5, 6]. It has been suggested
that specific biological characteristics might explain the ad-
verse prognosis of BC in Africa [7, 8].
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BC is a heterogeneous disease with different morphological
and molecular subtypes [9, 10]. The treatment and routine clin-
ical management of BC rely on hormonal receptor (HR) status
such as the presence or absence of estrogen receptor (ER),
progesterone receptor (PR), and human epidermal growth fac-
tor 2 (HER2) combined with other prognostic factors such us
patient age, tumor histology, tumor stage, and nodal status [11,
12]. A combination of ER, PR, and HER2 defines distinct
tumor classes of BC that are further defined by gene expression
profiles. The knowledge of tumor subtype may enable more
accurate diagnoses and support therapeutic decisions. In clinical
settings, tumor subtypes are classified using immunohisto-
chemistry (IHC)markers and guide prognosis and targeted ther-
apies for ER/PR or HER2 positive tumors. ER/PR positive
tumors are candidate for hormonal (endocrine) therapy, where-
as HER2 positive tumors are targeted with anti-HER2 thera-
pies. Triple negative (ERnegative, PR negative, HER2 nega-
tive) tumors lack any target therapy [13].
Little is known about the rate and features of BC in Africa.
The few studies conducted in SSA on clinico-pathological and
biological characteristics of BC report that it is characterized
by an early age of onset and an advanced stage at diagnosis
with poor prognosis. However, the reports concerning hor-
mone receptor and molecular subtypes are contradictory. A
review by Brinton et al. [14] found that most breast tumors
in African women are hormone receptor negative, while
others reported the predominance of hormone receptor posi-
tive breast tumors.
In the present study, we aimed at providing information on
the clinical presentation and hormonal receptor profiles of
breast cancer in Rwanda through a large collection of cases
from three major hospitals. We also compared our results with
reports from previous studies in other SSA countries.
Material and Methods
Study Design and Setting
This is a descriptive retrospective study conducted at three
referral hospitals in Rwanda: University Teaching Hospital
of Butare (CHUB) located in the Southern province,
University Teaching Hospital of Kigali (CHUK), and
Rwanda Military Hospital (RMH) at Kanombe, both located
in Kigali, capital city of Rwanda. BC patients are referred
from all over the country to these three referral hospitals.
Data Collection
Data including hormonal profile (ER, PR) and HER2 expres-
sion, demographic information (gender, age at diagnosis), and
tumor characteristics (tumor stage or grade) were collected
through review of patients electronic medical records from
January 2015 to December 2018. Immunohistochemistry
(IHC) staining for ER, PR, and HER2 was performed at one
referral hospital. The biopsy or surgical specimens received
from all three hospitals were originally fixed in 10% formalin.
They were then fixed in 10% neutral buffered formalin for 24
to 72 h and then processed for routine hematoxylin and eosin
staining through the steps of dehydration, clearing, paraffin
impregnation, and finally sectioning and staining. Hormonal
receptor and HER2 statuses were identified by immunohisto-
chemical (IHC) markers using EnVision™ Flex Kit (Dako,
Denmark)–Manual protocol, and following the manufacturer
instructions. For each run of staining, a positive and negative
control slide was also prepared. The positive control slides
were prepared from breast carcinoma known to be positive
for the antigen under study. The negative control slides were
prepared from the same tissue block but incubated with PBS
instead of the primary antibody. A semi-quantitative histo-
chemical score was used to record results of ER and PR stain-
ing according to the system established by Allred et al. [15].
This system considers both the pro-portion and intensity of
stained cells. The intensity score (IS) ranges from 0 to 3, with
0 being no staining, 1 weak staining, 2 moderate staining, and
3 strong staining. The proportion score (PS) estimates the
proportion of positive tumor cells and ranges from 0 to 5, with
0 being non-reacting, 1 for 1% reacting tumor cells, 2 for 10%,
3 for one-third, 4 for two-thirds, and 5 if 100% of tumor cells
show reactivity. The PS and IS are added to obtain a total
score (TS) that ranges from 0 to 8. Tumor cells with a total
score of 3 to 8 were considered positive, whereas those with
TS less than 3 were considered negative cases.
Her-2/neu was scored on a 0 to 3 scale according to the
criteria for Intensity and Pattern of Cell Membrane Staining
with pathway HER2. The staining was scored as negative (0)
when no membrane staining was observed, or (1+) when
membranous staining was faint, partial staining of the mem-
brane in any proportion of the cancer cells; weakly positive
(2+) if weak complete staining of the membrane, greater than
10% of cancer cells; and positive (3+) if intense complete
staining of the membrane, greater than 10% of cancer cells.
The procedure was standardized in comparison with the
Hercep Test (DAKO) kit. Tumor grades were classified using
the Nottingham Bloom-Richardson grading system [16], and
clinical tumor stages were classified according to American
Joint Committee on Cancer and TNM classification [17]. All
histological evaluations and pathological reporting were in
compliance with the American Society of Clinical
Oncology/College of American Pathologists (ASCO/CAP)
Guidelines as updated (www.cap.org).
We also reviewed published studies from SSA countries
paying attention to data concerning the mean/median age, the
proportions of patients aged of 50 years or less, the percentage
of stage III&IV tumors, the percentage of triple negative tu-
mors, and the percentage of HER2-enriched tumors.
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Data Analysis
Data were organized into a secure, electronic database and
checked for duplications and errors by independent people.
We used descriptive statistics to report the mean and standard
deviation (SD) for continuous data and frequencies and pro-
portions for categorical data. Chi-square or ANOVA test was
used to evaluate the statistical significance of the association
between hormonal/ tumor subtypes with patient’s age and
tumor stage. We classified hormonal statuses into five tumor
subtypes: ER+, PR+, HER2+ (triple positive), ER−, PR−,
HER2− (triple negative), ER+, PR+, HER2−, ER−, PR−,
HER2+ (HER2-enriched), and others (ER−, PR+, HER2+;
ER−, PR+, HER2−; ER+, PR−, HER2−). To test for age,
two groups were considered: young (patients aged 50 years
and under) and old (patients above 50 years). The tumor
stages were divided into three categories: early stage (stages
I and II), locally advanced (stage III), and metastatic (IV).
Results from studies in SSA on proportions of young pa-
tients, advanced tumor stage, triple negative tumors, and
HER2-enriched were summarized in the table. Proportions
of triple negative tumors from those studies were grouped
according to geographical location in Africa and meta-
analyzed using an inverse variance method. The proportion
estimates were calculated under the random effect model.
Confidence intervals for proportions were calculated using
the exact binomial method.
The significance level was fixed at 5%. Data analysis was
performed using SPSS Inc., Chicago, IL, USA, version 20,
and meta-proportions were plotted using R software language.
Ethical Consideration
Ethical approval was obtained from the Institutional Review
Board of the College of Medicine and Health Sciences
(CMHS) at University of Rwanda (Reference No 209/
CMHS IRB/2017).
Results
Clinical Pathology Characteristics of Study
Participants
A total number of 138 breast cancer cases with available data
for all variables considered in the present study were recorded.
Of all cases, 98% was female while only 2% was male. The
mean age at diagnosis was 49.7 years (SD = 13) and ranged
from 17 to 86 years. The majority of patients (57.2%) were
diagnosed before the age of 50 years compared with 42.8%
aged > 50 years. Among these, 9.4% was younger than
35 years old. Bilateral breast cancer was recorded in 2
(1.4%) patients.
Histologically, invasive ductal carcinoma accounted for the
majority of the patients with 81.9% of cases, followed distant-
ly by invasive lobular carcinoma with 8.7%.
The tumor stage III was the commonest accounting for
62.5% (80/128) followed by stage II with 24.8%. Stage I
and stage IV represented 7.0% and 7.8% of all cases,
respectively.
Lymph node invasion was observed in the majority of pa-
tients 70.6% (77/109) compared with 29.4% (32/109) node
negative tumors (Table 1).
Hormonal Receptor Profiles in Relation with Age and
Tumor Stage at Presentation
In general, hormonal receptor negative tumors were predom-
inant compared with hormonal receptor positive: 55.1% ER−
Table 1 Clinical pathology characteristics of study participants
Variables Frequency (n = 138) Percentage
Age: mean ± SD: 49.7 ± 12.98
Range 17–86












Ductal carcinoma in situ 2 1.4
Invasive ductal carcinoma 113 81.9
Invasive lobular carcinoma 12 8.7
Medullary 5 3.6
Metaplastic 3 2.2
Sarcoma of the breast 1 0.7












vs. 44.9% ER+, 63.8% PR− vs. 36.2 PR+, and 78.3% HER2−
vs. 21.7 HER2+. Hormonal receptor negative tumors were
most common in the younger age group (≤ 50 years) and at
advanced tumor stages. However, the association between age
and hormonal status was not statistically significant (p > 0.05).
We observed a statistically significant association between
tumor stage and ER status (p = 0.00097). However, the asso-
ciation between PR, HER2, and tumor stages was not statisti-
cally significant (p > 0.05) (Table 2).
The most commonly detected tumor subtype was triple
negative (ER−, PR−, HER2−) representing 37.7% of all
cases, followed by ER+, PR+, HER2− with 31.2% of
cases, and HER2−enriched (ER−, PR−, HER2+) with
14.5% of cases. The mean ages across all tumor subtypes
were not statistically significantly different (p = 0.558).
Across all tumor subtypes, the majority of patients had
locally advanced tumors and was in the younger age group.
However, the relationship between tumor subtypes, tumor
stage, and age of patients was not statistically significant
(p = 0.097) (Table 3).
Age at Diagnosis, Tumor Stage, and Molecular
Subtypes of Breast Cancer in SSA
The results reported in previous studies conducted in SSA
countries evaluating the age at diagnosis, tumor stage, and
tumor subtypes of breast cancers are aggregated in
Table 4. These results showed a high proportion of young
patients in SSA (52–86%) with median ages ranging be-
tween 42 and 53 years. Tumor stage III was observed in
38–81%. The overall proportion of triple negative subtype
was 31% ranging from 15 to 53% with the highest pro-
portions in Western countries compared with East and
Southern countries (Fig. 1).
Discussion
The risk factors associated with BC disease in Africa and in
Rwanda are still unknown. The increasing incidence is
thought to be linked to an increase in life expectancy, adoption
of western lifestyle including contraceptive use, and possible
specific genetic predisposition [34].
Several studies in SSA reported the high prevalence of BC
at younger ages with late stage at diagnosis and poor progno-
sis compared with western countries. Nevertheless, the results
on hormone receptor and molecular subtype distribution in
African population are still unclear [14].
In the present study, we analyzed the data from 138 con-
firmed BC cases, evaluating the association between age at
diagnosis, tumor stage at presentation, and hormonal receptor
profiles or subtypes.
We found that BC in Rwanda occurs at younger age with a
mean age of 49 (SD = 13) and most patients (57.2%) below
50 years of age while 42.8% of patients were above 50 years.
Furthermore, breast cancer was commonly diagnosed be-
tween 35 years and 50 years of age with 47.8% of all cases
in this age range. The same observations were made in other
SSA countries (Table 4). This finding raises the question of
the implication of demographic, genetic, and environmental
factors in BC development. The high frequency of young BC
patients in Rwanda could be influenced by the demographics
in Africa and in Rwanda, where a high number of women are
aged less than 50 years in comparison to Europeans [35]
(Fig. 2). For example, the Belgian and Rwandan demographic
graphs indicate that with similar numbers of total inhabitants,
the absolute numbers of women aged 30–49 or 50–69 are
similar in Belgium, while in Rwanda, there are 2.4 times more
women in the 30–49 than in the 50–69 age range. As there are
52.2% cancers in the 30–49 range vs. 37.7% in the 50–69
range, more than half of the difference when comparing with
Table 2 The relationship
between hormonal receptor
statuses, age at diagnosis, and
tumor stages
HR n (%) ER PR HER2
Age n (%) ER− ER+ PR− PR+ HER2− HER2+
≤ 50 years
n = 79
42 (55.3) 37 (59.7) 47 (53.4) 32 (64.0) 60 (55.6) 19 (63.3)
> 50 years
n = 59
34 (44.7) 25 (40.3) 41 (46.6) 18 (36.0) 48 (44.4) 11 (36.7)
p value 0.72 0.30 0.533
Locally advanced
n = 73
52 (68.4) 21 (33.9) 55 (62.5) 18 (36.0) 56 (51.8) 17 (56.7)
Metastatic
n = 10
4 (5.3) 6 (9.7) 7 (7.9) 3 (6.0) 6 (5.6) 4 (1.3)
Missing+ 2 (2.6) 6 (9.7) 4 (4.5) 4 (8.0) 8 (7.4) 0 (0.0)
p value 0.00097* 0.0642 0. 483
*Statistically significative
+Missing data were not considered in the analysis
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European countries can be explained by the demographic ef-
fect. Moreover, it has been estimated that mammography
screening programs targeting women between 50 and 69 lead
to an over-diagnosis rate of 12–20%, and thus further increase
the number of diagnoses in that age range in Europe [36].
Taking together these aspects, it is difficult to conclude that
the mean age of BC incidence in significantly lower in SSA
than in European countries.
Breast tumor stage is considered as a major determinant of
survival from breast cancer where early stage tumor is associ-
ated with a better prognosis and a higher survival rate than
advanced or tumors [15, 36]. In our study, tumor stage III was
the most common with 62%, while metastatic tumors (stage
IV) represented 7.8% of cases. More than 50% of patients
were clinically node positive at presentation. The high fre-
quency of advanced BC in our settings is due to a delay in
seeking treatment or a system delay in providing care. The
reasons for delay in seeking treatment could be the low edu-
cational level of patients, a lack of awareness about BC and
associated healthcare, cultural beliefs, and fear of not being
considered desirable by marriage partners after mastectomy.
In addition, health care services can also be at a long distance
from home for the majority of patients. Finally, in many parts
of Africa, Rwanda included, patients first consult traditional
healers before going to hospitals. System delay can be due to
an insufficient medical infrastructure and trained personnel to
handle the disease, as well as to the structure of health system
in Rwanda. Many Rwandan patients are covered by public
insurance, and they have to fist consults a local health center
then obtain a transfer to a district hospital before accessing a
high-level health care provider at a referral hospital. This
complicated channel results in disease progression and delays
in proper diagnosis and treatment [8].
The relatively young age of women with BC and the pre-
dominance of advanced tumor stages were reported in several
studies in SSA [19, 37–43]. In Western countries the majority
of BC patients present when they are still at a early stage, with
a mean age greater than 60 years old, more than 10 years older
than in African countries [44, 45].
With regard to hormonal receptor and tumor subtypes
profiles, hormonal receptor negative and TN subtype tu-
mors were the most predominant with 55.1% ER−, 63.8%
PR−, 78.3 HER2−, and 37.7% TN tumors. No statistically
significant association between hormonal receptors, tumor
subtypes, and age of patients was observed (p > 0.05).
However, a statistically significant association was ob-
served between ER status and tumor stage (p = 0.0009).
The predominance of hormone receptor negative observed
in our study participants may be due to the biological
characteristics of patients, or to the poor tissue handling.
Tissues that are damaged by poor tissue handling are
more likely to have incorrect IHC results and may be
more likely to be interpreted as TN. Rugwizangoga
et al. [46] showed that in our setting only 23.6% of tissues
was processed properly; but the authors did not find any
statistical significance between duration of tissue fixation
and molecular characteristics of tumors.
Nevertheless, our findings were consistent with other find-
ings reported in African American (AA) and European wom-
enwith African Descent [47, 48]. Studies in African American
women reported that the prevalence of TNBC and was 2–3
fold higher compared with White women, ranging from 29.8
Table 3 Tumor subtypes in relation to age at diagnosis and tumor stages
Tumor subtype ER + PR + HER2+
(Triple positive)
ER + PR + HER2− ER − PR − HER2+
(HER2-enriched)
ER − PR − HER2−
(Triple negative)
Others p value
7 (5.1) 43 (31.2) 20 (14.5) 52 (37.7) 16 (11.6)
Mean ± SD 47.3 ± 9.9 49.9 ± 11.9 47.3 ± 10.1 51.9 ± 14.7 47.3 ± 12.9 0.558
Age ≤ 50 years 0.752
n = 79 4 (57.1) 26 (60.5) 13 (65.0) 26 (50.0) 10 (62.5)
Age > 50 years
n = 59 3 (42.9) 17 (39.5) 7 (35.0) 26 (50.0) 6 (37.5)
Tumor stage: n (%)
Early stage 0.097
n = 47 2 (28.6) 23 (53.5) 5 (25.0) 12 (23.1) 5 (31.3)
Locally advanced
n = 73 3 (42.8) 12 (27.9) 13 (65.0) 36 (69.2) 9 (56.2)
Metastatic
n = 10
2 (28.6) 4 (9.3) 2 (10.0) 2 (3.8) 0
Missing+
n = 8
0 4 (9.3) 0 2 (3.8) 2 (12.5)
*Statistically significant
+Missing data were not considered in analysis
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[24] to 46.6% [49]. For example, Carey et al. [50] in Carolina
Breast Cancer Study found the predominance of TN tumor in
AA women in comparison to White American women (39%
vs16%). Clarke et al. [51] and Lund et sal. [49] reported a
higher rate of TN cases in black women compared with white
women in each age group [51]. Keenan et al. [52] made sim-
ilar conclusions after analyzing TN cases from The Cancer
Genome Atlas (TCGA) and showed that TN and basal tumors
were more prevalent in AA in comparison to white women
(33.3% vs. 14.19% TN and 34.8% vs. 16.1 basal). In UK,
Bowen et al. amazed data from UK-based BC cohort and
found that 22% of black women had TN tumors in compari-
son to 15% of white women [53].
Inversely, in Western countries, BC is shown to be hor-
mone receptor positive in 70–80% and only 10–20% of tu-
mors are found to be TN [54–56].
Table 4 Comparison of distribution of aggressive molecular subtypes, younger age at diagnosis, and advanced tumor stage of breast cancer from
selected Sub-Saharan African studies
























Our study Rwanda 138 49.7 ± 12.9 79 (57.2) 73/128 (57.03) 10/128 (7.8) 52 (37.7) 20 (14.5)
Sayed et al.
(2014)





52 46 (25–82) 27 (51.9) 40 (76.9) NA 19 (38.4) 5 (9.6) [19]
Galukande et al.
(2014)
































Guinea 58 45 ± 14 32 (55.2) 28 (48.3) 11 (19.0) 15 (25.9) 13 (22.4) [26]
Ly et al.
(2012)
Mali, Bamako 114 48.8 ± 0.53 74 (68.0) 91 (80.0) 49 (43.0) 52 (46.0) 5 (4.0) [27]
Jiagge et al.
(2016)
Ghana, Kumasi 234 49 (24–92) NA 84 (53.8) NA 124 (53.2) 27 (11.6) [24]
Usman et al.
(2019)







Nigeria, South 123 46.9 ± 13 75 61.06) 66 (53.7) NA 50 (40.7) 13 (10.6) [29]
Titloye et al.
(2016)











1216 48.1 ± 13.1 472 (38.8) 533 (43.8) 107 (8.9) 246 (20.4) 117 (11.04) [32]
Miguel et al.
(2017)
Angola, Luanda 140 47 (24–84) NA 91 (65.0) 5 (3.6) 44 (31.4) 22 (15.7) [33]
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To compare our results, we have reviewed the studies con-
ducted in SSA countries evaluating the age at diagnosis, stage
at presentation, and tumor subtypes (Table 4).
Studies conducted in Eastern African countries such as
Uganda [20], Tanzania [19], Erythrea, and Sudan [25], and
Ethiopia [22, 24] reported a predominance of hormone recep-
tor negative with proportions of TNBC slightly higher than in
the South of Africa. In this region where Rwanda is located,
the proportions of TN were compared with our results and
vary from 30 to 39%. Nevertheless, other studies from
Kenya [18] and Democratic Republic of Congo [21] reported
the predominance of hormone receptor positive with a low
proportion of TN tumors (20% and 15%, respectively).
In the Western region of Africa, the highest proportions of
hormones receptor negatives and TNBC tumors were reported.
A study conducted in six geographic areas of Nigeria and
Senegal showed that ER− negative tumors were the most pre-
dominant comprising 76% of cases. In Mali, Ly et al. found a
high frequency of TN tumors with 46% [27]. In Nigeria, the
frequency of TN tumors was 40–48% [54–56]. In Kumasi,
Ghana, the same high proportions of TN (53.2% and 53.8%)
were reported [22, 24]. However, studies conducted in
Southern African countries like South Africa, Namibia, and
Angola [18, 22, 25] found that the majority of tumors were
ER positive. TN tumors represented 20–32% with a high fre-
quency in black women as compared with white patients.
Figure 1 shows that the overall proportion of triple negative in
Africa was 31% (95% CI = 26–37%), which is superior to the
proportions of TNBC reported in Western countries (10–20%).
The distribution of hormone receptor negative and TN subtype
increases from South to North and from East/Middle to
Western Africa with a slight variability within each region.
This may be partly confirmed by the study conducted by
Jiagge et al., where ER negative and TNBC in Ghana (West
Africa) were higher with 71.1% and 53.8%, respectively, than
in Ethiopia (East Africa) with 28.6 ER negative and 15% of
TNBC [24]. In our study, the proportions of TNBC (37.7%)
observed from Rwanda (Middle Africa) was higher than obser-
vations made in Ethiopia, but less than the TN cases observed
in Ghana, suggesting that Middle Africa may be an intermedi-
ate between East and Western Africa. The differences of tumor
subtypes in SSA could be linked to environmental or genetic
factors related to geographical location but will have to be con-
firmed in large Pan-African studies with a uniquemethodology.
Fig. 1 Comparison of proportions of triple negative breast tumors reported in SSA studies














Fig. 2 Comparison of distribution of female population between Rwanda
and Belgium in relation to age
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A study conducted by Sung et al. confirmed the variability
of prevalence of TN breast tumors in black women according
to geographical origin. Sung et al. evaluated breast cancer
subtypes among Black American women in the USA from
different birthplaces and found that the proportion of TNBC
was higher in US born followed by Western-Africa born
followed by Caribbean-born and then Eastern-African black
born women [57]. Our findings add more evidence to the
suggestions made by Sung et al. that it is important to consider
geographical origin in studies characterizing BC in women
with African descent.
This is the first study that provides data on hormone pro-
files and tumor subtypes of BC in Rwanda compared with age
at diagnosis and tumor stages. One of the limitations of our
study was the lack of available data on hormonal receptor
status, age at diagnosis, and/or stage at presentation.
Therefore, a high number of patients were excluded from the
analysis because of missing data on these key variables con-
sidered in our study. In addition, information about patients’
treatment and mortality was often missing. This would have
allowed us to calculate the responses to treatment and survival
rate after diagnosis according to tumor subtypes.
Nevertheless, our results provide important information about
tumor characteristics of BC in Rwanda and in Africa. Future
large studies investigating BC in SSA are required.
Conclusion
The present study showed that in Rwanda,BC is characterized
by the predominance of hormone negative and triple negative
tumor subtypes, with a young age at diagnosis and a high
frequency of advanced tumors. However, no statistically sig-
nificant association of tumor subtypes, age, and tumor stage
was observed. Larger prospective studies of BC series are
necessary to confirm the present results and to provide an
accurate portrait of the disease presentation and progression
in various African regions for a better disease management.
Indeed, our findings and results from other SSA studies
suggest that there is a geographic variability in the distribution
of hormonal receptor and tumor subtypes. Further confirma-
tory studies could examine genetics and environmental factors
that may play a role in the differences of tumor characteristics
in SSA populations.
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